A utoimmune hepatitis (AIH) is a chronic inflammatory liver disease that has a prevalence of approximately 1 in 10,000 in the United States and Europe and accounts for 2%-6% of all liver transplantations. 1 AIH is diagnosed by increased alanine aminotransferase levels, an intrahepatic lymphocytic mononuclear cell infiltrate, hypergammaglobulinemia, and autoantibodies, and the absence of liver disease of viral, toxic, or metabolic etiology. 2, 3 Autoantibodies target nuclear antigens (antinuclear antibodies), smooth muscle antigens, liver-kidney microsomes, and/or soluble liver antigen/liver pancreas antigen (SLA/LP). Autoantibodies to SLA/LP are detectable in about 20% of AIH cases, 4, 5 and are unique in that they are the only autoantibodies specific for AIH. 4 The target of SLA/LP autoantibodies has been cloned 6 and named SEPSECS by the Nomenclature Commission of the Human Genome Organization. However, even though autoantibodies are well accepted as serologic markers for diagnosis and classification of AIH, it is still unclear whether they play any role in disease pathogenesis. 7 The degree of the intrahepatic lymphocytic infiltrate, the histologic hallmark of AIH, correlates well with disease progression and is therefore thought to contribute directly to disease pathogenesis. The clonal restriction of the intrahepatic T-cell population and the observation that HLA-DRB1*0301 and HLA-DRB1*0401 predispose to AIH and influence disease severity 8, 9 have led to the hypothesis that intrahepatic CD4 ϩ T cells recognize self-antigens in the context of HLA-DRB1*0301 and HLA-DRB1*0401. 2 HLA-DRB1*0301, the principal AIH susceptibility allele among white Europeans and Americans, 8, 9 and HLA-DRB1*0401 may even present the same autoantigen to CD4 ϩ T cells because both alleles share an amino acid motif in their antigen binding groove (shared binding hypothesis). 10 Despite much effort, it still remains unknown which autoantigens HLA-DRB1*0301 and HLA-DRB1*0401-restricted CD4 ϩ T cells recognize in AIH. This question has been declared a high priority investigational challenge, 11 but has proven difficult to answer for the following reasons. As in other autoimmune diseases, 12 the frequency of autoreactive CD4 ϩ T cells in the peripheral blood is too low to screen a large number of candidate peptides for T-cell recognition. Autoreactive CD4 ϩ T cells are presumably more frequent at the site of inflammation, but only a small piece of tissue and thereby only a small number of lymphocytes can be obtained by liver biopsy. It therefore remains necessary to expand and/or clone liver-biopsy-derived T cells in vitro before they can be studied in functional assays. 13 This approach renders an ex vivo assessment of the number and function of autoantigen-specific T cells impossible. Furthermore, assays that solely rely on the function of autoantigenspecific T cells often are compromised because of immunosuppressive therapy of AIH.
We therefore immunized humanized mice, which are transgenic for HLA-DRB1*0301 and do not express murine major histocompatibility complex class II, 14 with the recently cloned SLA/LP autoantigen 6 and established Tcell hybridomas to identify the optimal DRB1*0301-restricted sequences (epitopes) within SLA/LP (Figure 1 ). These epitopes then were used in enzyme-linked immunospot (ELISpot) assays and in flow cytometry assays with custom-made fluorescently labeled tetrameric DRB1*0301 complexes to monitor AIH-specific T-cell responses in the blood of patients with AIH. The identification of these T-cell epitopes also may be a step towards the identification of those immunogenic self-and/or cross-reactive foreign antigens that set off the initial autoimmune reaction.
Materials and Methods

SLA/LP Protein, Peptides, Tetramer, and Antibodies
Recombinant human SLA/LP (AAD33963) was synthesized and purified as previously described. 6 Twentymer peptides overlapping by 12 amino acids (aa) and spanning aa 1-422 of human SLA/LP (Mimotopes, Clayton, Australia), shorter SLA/LP peptides, and the DRB1*0301-restricted hepatitis C virus (HCV) peptide HCV 261-269 (VLVLNPSVA) 15 (Facility for Biotechnology Resources, CBER, FDA, Bethesda, MD) were resuspended at 20 mg/mL in dimethyl sulfoxide and diluted with phosphate-buffered saline solution (PBS) to 2 mg/mL. Tetramers DRB1*0301-SLA/LP 184 -198 and DRB1*0301-SLA/LP 373-386 were custom-made by Beckman Coulter (Fullerton, CA).
Anti-mouse CD4-phycoerythrin (PE) or -fluorescein isothiocyanate (clone 129.19), CD3e-allophycocyanin (APC)-Cy7 (clone 145-2C11), CD19-PE (clone 1D3), CD11a-PE-Cy7 (clone 2D7), CD62L-APC (clone MEL-14), and antihuman CD3-APC (clone UCHT1), CD4-PE-Cy7 or -APCCy7 (clone SK3), CD25-APC-Cy7 (clone MA 251), CD8-PE-Cy5 or -peridinin chlorophyll protein (PerCP) (clone RPA T-8), CD14-PerCP (clone M⌽P9), CD16-PE-Cy5 (clone 3G8), HLA-DR-fluorescein isothiocyanate (clone L243), and CD19-PE-Cy5 or -PerCP (clone HIB 19), as well as purified antibodies to I-A/I-E (clone 2G9), HLA-DR, -DP, -DQ (clone TÜ 39) were purchased from BD Pharmingen (San Diego, CA). Anti-human CD14-PE-Cy5 (clone TÜ K4) was purchased from Serotec (Raleigh, NC).
Mouse Immunization
C57BL/6 mice (Jackson Laboratories, Bar Harbor, ME) and HLA-DRB1*0301-transgenic mice that do not express endogenous class II at detectable levels (DR3.AB0) 14 were maintained in a clean conventional facility. Experiments were approved by the Animal Care and Use Committee of the National Institute of Diabetes and Digestive and Kidney Diseases.
Eight-to 12-week-old mice were immunized at the base of the tail and both hind foot pads with the following: (1) 40 g of human recombinant SLA/LP (11 mice) (2) 50 g of peptides SLA/LP 81-100 , SLA/LP 89 -108 , and SLA/LP 97-116 (5 mice), (3) 50 g of peptides SLA/LP [177] [178] [179] [180] [181] [182] [183] [184] [185] [186] [187] [188] [189] [190] [191] [192] [193] [194] [195] [196] and SLA/LP 185-204 (5 mice), or (4) 50 g of peptides SLA/LP [403] [404] [405] [406] [407] [408] [409] [410] [411] [412] [413] [414] [415] [416] and SLA/LP 408 -418 (5 mice), in 100 -200 L PBS emulsified with an equal amount of AS01B adjuvant (GlaxoSmithKline, Rixensart, Belgium), 16 re-immunized after 3 weeks, and killed 10 days after the last immunization. Lymphocytes were isolated by either mechanical disruption or enzymatic digestion (400 ug/mL Liberase CI; Roche Diagnostics, Indianapolis, IN) of draining lymph nodes and spleen, followed by filtration through a 70-m nylon cell strainer (BD Falcon, Bedford, MA) and red blood cell lysis with ACK lysing buffer (Bio-Whittaker, Walkersville, MD).
Analysis of the Humoral Immune Response
SLA/LP-specific antibodies were detected with the QUANTA Lite SLA/LP enzyme immunoassay (EIA) kit (Inova Diagnostics, San Diego, CA) according to the manufacturer's instructions except for the use of a horseradish-peroxidase-labeled polyclonal goat anti-mouse Ig (BD Pharmingen, dilution 1:2000) for detection. Isotyping was performed with a mouse immunoglobulin screening/isotyping kit (Zymed Laboratories, San Francisco, CA). Fine mapping of the antibody specificity was performed by EIA with 1/100 dilutions of sera using microtiter plates (Falcon) coated with SLA/LP-overlapping peptides (10 g/mL).
Analysis of the Cellular Immune Response of Immunized Mice
Proliferation assays. Quadruplicate cultures of 5 ϫ 10 5 mouse spleen cells were stimulated for 3 days with or without human recombinant SLA/LP at the indicated concentration or with 10 ng/mL phorbol myristic acetate/1 mol/L ionomycin (Sigma-Aldrich, St. Louis, MO) in 96-well, round-bottom plates in RPMI 1640 containing 10% heat-inactivated fetal bovine serum (Bio-Whittaker), 50 mol/L ␤-mercaptoethanol (Invitrogen, Carlsbad, CA), 100 U/mL penicillin, 100 g/mL streptomycin, 2 mmol/L L-glutamine, 10 mmol/L HEPES, and 1 mmol/L sodium pyruvate (Cellgro, Herndon, VA). For the last 16 hours, 1 Ci 3 H-thymidine (ICN, Costa Mesa, CA) was added per well. Cells were harvested with a Packard Filtermate 96-well-harvester (Perkin Elmer, Wellesley, MA) and incorporated radioactivity was measured with a Packard Topcount (Perkin Elmer).
ELISpot assays. Ex vivo ELISpot assays were performed as described 17 with the following modifications. Triplicate cultures of 5 ϫ 10 5 splenocytes were stimulated with or without recombinant SLA/LP (2.5 g/mL), synthetic peptides (10 g/mL), or phorbol myristic acetate/ionomycin on plates coated with 2 g/mL antimouse interleukin-2 (IL-2) (clone JES6-1A12; BD Pharmingen). Biotin-conjugated anti-mouse IL-2 antibody (2 g/mL, clone JES6-SH4; BD Pharmingen) and 3-amino-9-ethylcarbazole substrate solution (Sigma-Aldrich) were used for detection. Spots were counted with a KS ELISpot Reader (Carl Zeiss Inc, Thornwood, NY).
Tetramer analysis. CD4 ϩ T cells were negatively isolated from spleen and lymph node cells with magnetic beads and magnetic cell sorting columns (Miltenyi Biotec, Auburn, CA), incubated for 10 minutes with anti-CD16/anti-CD32 as Fc-block (clone 2.4G2; BD Pharmingen), washed, and stained with 2.5 g/mL ethidium monoazide (EMA; Sigma-Aldrich) under a fluorescent light source for 10 minutes. Cells were washed again, and stained with 10 L of either DRB1*0301-SLA/LP 184 -198 -tetramer or DRB1*0301-SLA/LP 373-386 -tetramer in the presence of unconjugated anti-mouse T cell receptor (TCR)-␤ (clone H57-597; eBiosciences, San Diego, CA) at 37°C for 3 hours. After addition of antibodies against cell surface molecules for the last 30 minutes, cells were washed and analyzed on an LSRII flow cytometer using FACS Diva (both BD Biosciences, San Jose, CA) and FlowJo (TreeStar, San Carlos, CA) software. EMA ϩ (dead) cells were excluded and CD3 ϩ CD4 ϩ T cells were analyzed for DRB1*0301/epitope-tetramer binding and expression of CD62L and CD11a. 
Detection of SLA/LP-Specific CD4 ؉ T Cells in Human Beings
Peripheral blood mononuclear cells (PBMCs) were isolated from 9 patients with anti-SLA/LP ϩ AIH and, as negative controls, from an HLA-DRB1*0301 Ϫ patient with anti-SLA/LP ϩ AIH and 2 HLA-DRB1*0301 ϩ , anti-SLA/LP Ϫ patients with a past history of hepatitis B (antihepatitis B surface antigen positive, anti-hepatitis B e antigen positive, hepatitis B surface antigen negative, hepatitis B e antigen negative). Patients were followed up either at Johannes Gutenberg Universität (Mainz, Germany), Universitätsklinikum Hamburg Eppendorf (Hamburg, Germany), Medizinische Universitätsklinik (Freiburg, Germany), or the Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health (Bethesda, MD), and provided informed consent under protocols approved by the Ethics Committee and Institutional Review Board of the respective institutions.
Thawed PBMCs were stained with 2.5 g/mL EMA under a fluorescent light source for 10 minutes, washed in PBS, and stained with 10 L of either the DRB1*0301-SLA/LP 373-386 tetramer or the DRB1*0301-SLA/LP 184 -196 tetramer (both coupled to PE) in complete RPMI medium for 30 minutes at 37°C. After washing in PBS, cells were stained with antibodies against CD3, CD8, CD14, and CD19 and CD4 antibodies for 20 minutes at 4°C, washed, and subsequently treated with anti-PE magnetic beads (Miltenyi Biotec) for 15 minutes at 4°C. Ten per- 
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cent of the cells were analyzed directly by flow cytometry (pre-enrichment sample), the remaining 90% were applied to MS columns (Miltenyi Biotec) to enrich PE-conjugated tetramer ϩ cells (postenrichment sample). After exclusion of doublets by flow cytometry, forward and side-scatter gating of lymphocytes and exclusion of EMA/CD8/ CD14/CD19 ϩ events, the CD3 ϩ T-cell population was analyzed for expression of CD4 and for tetramer binding.
For proliferation assays, 10 7 PBMCs were stained with 1 mol/L carboxyfluorescein diacetate succinimidylester (Molecular Probes, Eugene, OR) in 2 mL PBS for 5 minutes at room temperature. After addition of 5 mL fetal calf serum and 3 washes in PBS, cells were stimulated with 10 g/mL DRB1*0301-restricted SLA/LP 373-386 peptide or the DRB1*0301-restricted HCV 261-269 control peptide, 15 respectively. Forty U/mL of recombinant IL-2 was added on days 4 and 7. On day 10, cells were stained with EMA, the respective DRB1*0301/epitope-tetramer and antibodies against cell surface proteins, and analyzed by flow cytometry. After EMA/CD8/CD14/CD16/CD19 exclusion, CD3 ϩ CD4 ϩ lymphocytes were analyzed for tetramer binding and carboxyfluorescein diacetate succinimidylester content.
For interferon-␥ ELISpot assays, CD4ϩ T cells were isolated with the Miltenyi Multisort Kit (Miltenyi Biotec), released from the beads, stained with the DRB1*0301-SLA/LP 373-386 tetramer or the DRB1*0301-SLA/LP 184 -196 tetramer as described earlier, and sorted manually with anti-PE beads (Miltenyi Biotec) following the manufacturer's protocol. Part of the tetramer-enriched cell population was used directly in an ELISpot, the other part was expanded with 40 ng/mL anti-CD3 under a twice-weekly addition of 200 U/mL IL-2, 10 ng/mL IL-7, and 100 ng/mL IL-15 before ELISpot analysis. Interferon-␥ ELISpot assays were performed as described 19 
Results
Humoral Immune Response of HLA-DRB1*0301 Transgenic Mice to Human Recombinant SLA/LP
Sixteen DRB1*0301-transgenic mice were immunized subcutaneously with human recombinant SLA/LP and AS01B adjuvant. 16 As shown in Figure 2A , SLA/LP- specific antibodies were detectable after a single immunization and increased further after a booster immunization. Isotyping revealed a large IgG1, IgG2b, and IgG3 fraction ( Figure 2B ) consistent with a strong Th2 CD4 ϩ T-cell response in the context of this adjuvant. 16 Because the humoral immune response of patients with AIH is targeted against the carboxyterminus of SLA/LP, 4 antibodies against this region were mapped with overlapping 20mer peptides. As shown in Figure 2C , the 20mer peptide spanning aa 403-422 elicited the most vigorous response in HLA-DRB1*0301-transgenic mice. This peptide was recognized significantly less vigorously by nontransgenic C57BL/6 mice, suggesting a role of HLA-DRrestricted CD4 ϩ T-cell help in the generation of these autoantibodies.
Cellular Immune Response to SLA/LP in HLA-DRB1*0301 Transgenic Mice
Spleen-derived T cells of SLA/LP-immunized HLA-DRB1*0301-transgenic mice proliferated ( Figure 3A ) and produced IL-2 ( Figure 3B Figure 3C ).
To fine-map the immunodominant regions, T cells of SLA/LP-immunized HLA-DRB1*0301-transgenic mice were fused with the lymphoma cell line BWZ.36. The generated CD4 ϩ T-cell hybridomas recognized peptides spanning SLA/LP positions 1-20, 257-276, and 369 -388, respectively, indicating that these sequences were immunodominant ( Figure 2C ). To increase the efficiency of T-cell hybridoma generation against sequences that were recognized less vigorously, additional groups of 5 HLA-DRB1*0301-transgenic mice subsequently were immunized with peptide mix SLA/LP 81 [185] [186] [187] [188] [189] [190] [191] [192] [193] [194] [195] [196] [197] [198] [199] [200] [201] [202] [203] [204] . No T-cell hybridomas were generated for SLA/LP 81-116 and SLA/LP 400 -422 , indicating that CD4 T cells with these specificities were at low frequency or did not respond well to in vitro stimulation.
Fine Specificity of the SLA/LP-Specific T Cells
Stimulation of T-cell hybridoma with their cognate peptide activated the ␤-galactosidase reporter gene and resulted in a color reaction. The immunogenic 20mer peptide SLA/LP 369 -388 was of specific interest (Figure 4A , top bar) because it overlapped with the SLA/LP sequence that is recognized by antibodies of patients with AIH. 4 T-cell recognition increased further when 3 amino acids were removed from the aminoterminus and 2 or 3 amino acids were removed from the carboxyterminus ( Figure 4A ). T-cell recognition was abrogated, however, on further stepwise truncation of the peptide and peptide SLA/LP 373-386 NRLDRCLKAVRKER was identified as the optimal epitope ( Figure 4A , underlined sequence) and con- To analyze major histocompatibility complex restriction, the same T-cell hybridoma then was stimulated with the optimal peptide and DRB1*0301 ϩ spleen cells in the context of I-A/I-E antibody, HLA-DR antibody, or an isotype control. Recognition of peptide SLA/LP 373-386 was inhibited by HLA-DR antibodies, but not by I-A/I-E antibodies and isotype controls ( Figure  4B ), indicating that it was restricted by HLA-DR.
A second DRB1*0301-restricted optimal epitope was mapped in a similar way within the sequence of SLA/LP 184 -204 ( Figure 4C ). Stepwise amino-and carboxyterminal truncation identified peptide SLA/LP 186 -197 LIQQGARVGRID as the optimal epitope ( Figure 4A , Supplementary Figure 1B ; see Supplementary material online at www.gastrojournal.org) because deletion of either its aminoterminal lysine or its carboxyterminal aspartic acid reduced recognition. Antibody-blocking experiments revealed that this epitope also was restricted by HLA-DR ( Figure 4D ).
Next, we mapped the fine specificity of SLA/LP 257-276 -specific hybridomas (Supplementary Figure 2A, Figure 2A, third bar) . Removal of an arginine and lysine from the aminoterminus and a lysine from the carboxyterminal did not significantly reduce activation of the T-cell hybridomas. Recognition was abolished by further removal of glutamic acid from the aminoterminus, revealing SLA/LP 264-275 EMFSYLSNQIKK as the optimal epitope ( Supplementary Figure 2A and B; see Supplementary material online at www.gastrojournal. org). In contrast to the 2 epitopes identified in Figure 4 , this epitope was not restricted by HLA-DR because anti-I-A/anti-I-E rather than anti-HLA-DR antibodies blocked its recognition. Although DR3.AB0 transgenic mice do not express endogenous class II at a detectable level, they do express the murine Eb gene. 14 It is therefore possible that low-level expression of a DR␣/I-Eb fusion molecule was responsible for the presentation of this peptide.
Finally, using the same technique, the immunogenic epitope within SLA/LP [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] was identified as SLA/LP 7-18 CFWRRFIHGIGR (not shown). The sequence of this epitope is not present in the major SLA/LP splice variant (NM_153825), but only in the less-expressed splice variant derived from a Jurkat-cell complementary DNA library (NM_016955). 6 Because expression of the minor variant in liver is uncertain and the relevance of its recognition by liver-derived T cells thus is questionable, this epitope was not evaluated further.
In summary, the use of a humanized, HLA-DRB1*0301-transgenic mouse model resulted in the identification of 2 HLA-DR-restricted SLA/LP epitopes that are recognized by CD4 ϩ T cells and one of these epitopes ( Figure  4A and B) overlapped the sequence of the major B-cell autoantigen that is recognized by patients with anti-SLA/ LP ϩ AIH. 4 Next, we investigated whether the identified HLA-DR-restricted epitopes could be used to detect SLA/LP-specific CD4 ϩ T cells with fluorescently labeled tetrameric DRB1*0301 complexes. DRB1*0301-tetramers were synthesized for epitope SLA/LP 373-386 and attempted for epitope SLA/LP 186 -197 . Because the latter tetramer did not fold with the minimal epitope 
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SLA/LP 186 -197 , we chose a longer precursor peptide, SLA/LP 184 -198 , instead.
Both the DRB1*0301-SLA/LP 373-386 -tetramer and the DRB1*0301-SLA/LP 184 -198 -tetramer were first titered and validated with CD4 ϩ T cells of immunized HLA-DRB1*0301-transgenic mice. A large DRB1*0301-SLA/ LP 373-386 -tetramer ϩ CD4 ϩ T-cell population was identified in the spleens of 2 representative DRB1*0301-transgenic, immunized mice, but not in a DRB1*0301-transgenic, nonimmunized control mouse ( Figure 5A) . A CD4 ϩ T-cell population of similar size was detected with the second DRB1*0301-SLA/LP 184 -198 -tetramer ( Figure  5B ). Both DRB1*0301-tetramer ϩ CD4 ϩ T-cell populations expressed CD11a and, when compared with DRB1*0301/epitope-tetramer Ϫ CD4 ϩ T cells had downregulated CD62L expression, indicating loss of their lymph node homing potential as expected for antigen-induced effector T cells. Serum alanine aminotransferase levels remained within the upper limit of normal and no significant lymphocyte infiltrate was detected in the liver (not shown).
Detection of SLA/LP-Specific CD4 ؉ T Cells in the Blood of AIH Patients
As a proof of principle, we also studied PBMCs from patients with anti-SLA/LP ϩ AIH using the DRB1*0301-SLA/LP 373-386 -and DRB1*0301-SLA/LP 184 -198 -tetramers. As specificity controls, PBMCs from an HLA-DRB1*0301 Ϫ patient with anti-SLA/LP ϩ AIH and 2 HLA-DRB1*0301 ϩ anti-SLA/LP Ϫ patients with a past history of hepatitis B were studied in parallel. After gating on single cells and lymphocytes, EMA ϩ /CD8 ϩ /CD14 ϩ /CD19 ϩ cells were excluded and the CD3 ϩ cells were analyzed for CD4 expression and binding of the respective tetramer ( Figure 6A and B). Magnetic bead enrichment concentrated tetramer ϩ cells by a factor of 23-1042 (Table 1) . Overall, tetramer ϩ CD4 T cells were detected in PBMCs of 7 of 9 AIH patients after enrichment with anti-PE-labeled magnetic beads as compared with 0 of 3 (0%) control patients (P ϭ .045, Fisher exact test, Table 1 ). When carboxyfluorescein diacetate succinimidylester-labeled PBMCs were stimulated with the cognate SLA/LP 373-386 peptide more tetramer ϩ cells than tetramer Ϫ cells proliferated (47.0% vs 6.2%). In contrast, only 3.7% tetramer ϩ cells proliferated on stimulation with the unrelated, DRB1*0301-restricted HCV peptide HCV 261-269 ( Figure 6E ). 15 Finally, the newly identified CD4 T-cell epitopes also were tested in interferon-␥ ELISpot assays. As shown in Figure 7 , tetramer-enriched CD4ϩ T cells of HLA-DRB1*0301-positive AIH patients recognized both epitopes and produced interferon-␥, but tetramer-enriched CD4ϩ T cells of HLA-DR1B1*0301-negative AIH patients or DR1B1*0301-positive controls without AIH did not. These cells were tested ex vivo and after several weeks of antigen-nonspecific in vitro expansion with 40 ng/mL anti-CD3, 200 U/mL IL-2, 10 ng/mL IL-7, and 100 ng/mL IL-15. The rapid, antigennonspecific expansion protocol was chosen over a peptidespecific expansion protocol because of the very low number (Ͻ10 5 ) of tetramer-positive cells with which the expansion was started. ELISpot assays with the nonspecifically expanded T-cell lines ( Figure 7B , filled symbols) confirmed the ex vivo ELISpot results ( Figure 7B , open symbols).
Discussion
We here report that SLA/LP is not only targeted by humoral but also by cellular immune responses and describe 2 CD4 ϩ T-cell epitopes that are recognized in a DRB1*0301-restricted manner. CD4 ϩ T cells specific for these SLA/LP epitopes were detected in HLA-DRB1*0301-transgenic mice and in PBMCs of HLA-DRB1*0301-positive patients with AIH. Only HLA-DRB1* 0301-transgenic, but not nontransgenic, mice mounted SLA/LP-specific autoantibodies of the same specificity as in AIH in human beings, which suggests that HLA-DRB1*0301-restricted CD4 ϩ T cells shape the antibody repertoire in the context of the genetic background. Interestingly, one of the HLA-DR-restricted CD4 ϩ T-cell epitopes ( Figure 4A and B) was located in the carboxyterminal sequence of SLA/LP overlapping with the sequence that is recognized by antibodies. 4, 6 This close proximity of T-and B-cell epitopes within the SLA/LP autoantigen appears to be a characteristic of autoimmune diseases. 12, 20, 21 HLA-DRB1*0301-restricted, SLA/ LP-specific, CD4 ϩ T cells may, for example, help autoreactive B cells to produce autoantibodies and to secrete proinflammatory cytokines and chemokines that recruit plasma cells and CD8 ϩ T cells into the liver. Vice versa, autoantigen-specific B cells may bind and internalize SLA/LP via specific autoantibodies on their cell surface, process it into short peptides, and present these peptides on DRB1*0301 molecules to stimulate CD4 ϩ T cells. 22 The absence of liver disease in the SLA/LP-immunized HLA-DRB1*0301-transgenic mice was not unexpected. Recent studies on autoimmune diabetes have suggested that the frequency of autoantigen-specific T cells needs to be much higher (Ͼ80% of all CD8ϩ T cells in that study) and that additional inflammatory cytokine-and toll-like receptor-mediated signals are required to initiate autoimmune disease. 23 Furthermore, all published T-cell-mediated autoimmune models in HLA-transgenic mice involve organs other than the liver, 24, 25 which is characterized by a constitutive tolerogenic microenvironment. 26 Thus, additional factors, such as tissue destruction by unrelated mechanisms (toxic or infectious), might be necessary to induce intrahepatic inflammation and to trigger AIH. Because SLA/LP 6 and liver-kidney microsomes, the second cloned autoantigen in AIH, are cytosolic 
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enzymes, 27 it is possible that specific enzyme-substrate interactions initiate hepatocyte injury and death, 28 followed by transport of cell-associated autoantigens into the regional lymph nodes and priming of autoantigenspecific T and B cells.
In the analyzed patients with anti-SLA/LP ϩ AIH, the frequency of antigen-specific CD4 ϩ T cells detectable by ELISpot and tetramer analysis was in the same range as frequencies reported for other autoimmune diseases such as type I diabetes 29 and chronic infectious diseases such as Mycobacterium tuberculosis, 30 Borrelia burgdorferi, 31 and HCV infection. 32, 33 On immunosuppressive treatment, as was the case for the patients in our study, the frequency of autoreactive T cells may decrease further. In this scenario, enrichment of tetramer ϩ T cells with magnetic beads 32, 33 may increase the sensitivity of detection and allow their functional characterization.
The tetramer-staining profiles displayed a relatively low mean fluorescence intensity. Similar profiles have been reported for other major histocompatibility complex class II tetramers in the literature. 30 In this context, it recently was shown that CD4 ϩ T cells in blood, spleen, and lymph nodes differ in their major histocompatibility complex class II tetramer binding profiles, with tetramer ϩ T cells of lymph nodes and spleen showing higher mean fluorescence intensities than tetramer ϩ T cells in the blood. 34 The identified SLA/LP-specific T-cell epitopes and their corresponding tetramers should therefore be useful to monitor AIH-specific T cells during acute AIH and active disease progression and to study their role in the liver, the site of this disease.
